मूलभूत आँकड़े
| LEI | 549300ITFHW1YXFTGH91 |
| CIK | 1347613 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SYNERGY PHARMACEUTICALS INC DEL
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| May 2, 2019 |
Exhibit 99.1 SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP Lisa Laukitis Christine A. Okike Four Times Square New York, New York 10036-6522 Telephone: (212) 735-3000 Fax: (212) 735-2000 — and — Ron E. Meisler (admitted pro hac vice) Christopher M. Dressel (admitted pro hac vice) Jennifer Madden (admitted pro hac vice) 155 North Wacker Drive Chicago, Illinois 60606-1720 Telephone: (312) 407-0700 Fax: (3 |
|
| May 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 SYNERGY PHARMACEUTICALS, LLC (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Commissio |
|
| April 29, 2019 |
Exhibit 99.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re Chapter 11 SYNERGY PHARMACEUTICALS INC., et al., Case No. 18-14010 (JLG) Debtors.(1) Jointly Administered Related Docket Nos. 541, 546, 549, 632, 666, 671, 685, 687, 688, 689 & 690 FINDINGS OF FACT, CONCLUSIONS OF LAW AND ORDER CONFIRMING MODIFIED FOURTH AMENDED JOINT PLAN OF REORGANIZATION OF SYNERGY PHARMACEUTICALS I |
|
| April 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Commis |
|
| April 2, 2019 |
Exhibit 99.1 SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP Lisa Laukitis Christine A. Okike Four Times Square New York, New York 10036-6522 Telephone: (212) 735-3000 Fax: (212) 735-2000 — and — Ron E. Meisler (admitted pro hac vice) Christopher M. Dressel (admitted pro hac vice) Jennifer Madden (admitted pro hac vice) 155 North Wacker Drive Chicago, Illinois 60606-1720 Telephone: (312) 407-0700 Fax: (3 |
|
| April 2, 2019 |
FOURTH AMENDED JOINT PLAN OF REORGANIZATION OF SYNERGY PHARMACEUTICALS INC. AND ITS DEBTOR AFFILIATE Exhibit 99.2 SUBJECT TO FRE 408 CONFIDENTIAL UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re Chapter 11 SYNERGY PHARMACEUTICALS INC., et al., Case No. 18-14010 (JLG) Debtors.(1) Jointly Administered FOURTH AMENDED JOINT PLAN OF REORGANIZATION OF SYNERGY PHARMACEUTICALS INC. AND ITS DEBTOR AFFILIATE SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP Lisa Laukitis Ron E. Meisler Christine A |
|
| April 2, 2019 |
Financial Statements and Exhibits, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Commiss |
|
| March 14, 2019 |
Exhibit 99.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re Chapter 11 SYNERGY PHARMACEUTICALS INC., et al., Case No. 18-14010 (JLG) Debtors.(1) Jointly Administered THIRD AMENDED DISCLOSURE STATEMENT FOR THE THIRD AMENDED JOINT PLAN OF REORGANIZATION OF SYNERGY PHARMACEUTICALS INC. AND ITS DEBTOR AFFILIATE SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP Lisa Laukitis Ron E. Meisler C |
|
| March 14, 2019 |
Exhibit 99.2 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re Chapter 11 SYNERGY PHARMACEUTICALS INC., et al., Case No. 18-14010 (JLG) Debtors.(1) Jointly Administered THIRD AMENDED JOINT PLAN OF REORGANIZATION OF SYNERGY PHARMACEUTICALS INC. AND ITS DEBTOR AFFILIATE SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP Lisa Laukitis Ron E. Meisler Christine A. Okike Four Times Square Christo |
|
| March 14, 2019 |
Financial Statements and Exhibits, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Commis |
|
| March 8, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Commiss |
|
| March 6, 2019 |
Synergy Pharmaceuticals Announces Completion of Sale to Bausch Health Exhibit 99.2 Confidential – Not for External Distribution Synergy Pharmaceuticals Announces Completion of Sale to Bausch Health NEW YORK, March 6, 2019 – Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the “Company” or “Synergy”), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced sale of |
|
| March 6, 2019 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Commiss |
|
| March 6, 2019 |
Exhibit 99.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK Chapter 11 In re Case No. 18-14010 (JLG) SYNERGY PHARMACEUTICALS INC., et al., Jointly Administered Debtors.(1) Related Docket Nos. 17, 181, 183, 431 ORDER (A) APPROVING THE SALE OF SUBSTANTIALLY ALL OF THE DEBTORS’ ASSETS FREE AND CLEAR OF ALL CLAIMS, LIENS, RIGHTS, INTERESTS, AND ENCUMBRANCES, (B) AUTHORIZING THE DEBTORS T |
|
| March 2, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Commiss |
|
| March 2, 2019 |
Synergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch Health Exhibit 99.1 Synergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch Health NEW YORK, March 1, 2019 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the Company or Synergy), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced agreement with Bausch Health C |
|
| February 27, 2019 |
Synergy Pharmaceuticals Confirms Bausch Health as Successful Bidder for Its Business Assets Exhibit 99.1 Synergy Pharmaceuticals Confirms Bausch Health as Successful Bidder for Its Business Assets NEW YORK, February 26, 2019 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the “Company” or “Synergy”), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced agreement with Bausch Heal |
|
| February 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Com |
|
| February 11, 2019 |
SGYP / Synergy Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment synergypharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: Synergy Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 871639308 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check th |
|
| February 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Comm |
|
| January 10, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 a19-238118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2019 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| January 10, 2019 |
Exhibit 2.1 EXECUTION VERSION AMENDED AND RESTATED ASSET PURCHASE AGREEMENT BY AND AMONG SYNERGY PHARMACEUTICALS INC., SYNERGY ADVANCED PHARMACEUTICALS, INC., BAUSCH HEALTH COMPANIES INC. AND BAUSCH HEALTH IRELAND LIMITED DATED AS OF JANUARY 4, 2019 TABLE OF CONTENTS ARTICLE I THE ACQUISITION 6 Section 1.1. Acquired Assets 6 Section 1.2. Excluded Assets 8 Section 1.3. Assumed Liabilities 10 Sectio |
|
| January 2, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2018 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Com |
|
| December 18, 2018 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 a18-4167318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2018 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdic |
|
| December 13, 2018 |
Exhibit 10.1 EXECUTION SYNERGY PHARMACEUTICALS INC. SUPERPRIORITY DIP FACILITY Binding Term Sheet December 11, 2018 This binding term sheet (the “Binding Term Sheet”) sets forth the terms and conditions with respect to the New Money DIP Loans (as defined below), the DIP Facility (as defined below), the treatment of the Prepetition Obligations (as defined below), which terms and conditions will be |
|
| December 13, 2018 |
Exhibit 99.1 Press Release Synergy Pharmaceuticals Announces Agreement for Bausch Health to Acquire Its Business Assets Company Initiates Voluntary Chapter 11 Process to Effectuate Sale; Secures Commitment for DIP Financing to Support Normal-Course Operations NEW YORK, December 12, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) (the “Company” or “Synergy”), a biopharmaceutical company focused o |
|
| December 13, 2018 |
Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT BY AND AMONG SYNERGY PHARMACEUTICALS INC., SYNERGY ADVANCED PHARMACEUTICALS, INC., BAUSCH HEALTH COMPANIES INC. AND BAUSCH HEALTH IRELAND LIMITED DATED AS OF DECEMBER 11, 2018 TABLE OF CONTENTS ARTICLE I THE ACQUISITION 6 Section 1.1. Acquired Assets 6 Section 1.2. Excluded Assets 8 Section 1.3. Assumed Liabilities 9 Section 1.4. Excluded Liab |
|
| December 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2018 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction of incorporation) (Com |
|
| December 6, 2018 |
Exhibit 10.1 AMENDMENT TO LIMITED FORBEARANCE AGREEMENT This AMENDMENT TO LIMITED FORBEARANCE AGREEMENT is made as of December 5, 2018 (this “Amendment”), among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors (as defined in the Loan Agreement referred to below) party hereto, the Lenders (as defined in the Loan Agreement referred to below), and CRG Servi |
|
| December 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2018 Synergy Pharmaceuticals Inc. |
|
| November 26, 2018 |
Exhibit 10.1 Execution Version LIMITED FORBEARANCE AGREEMENT This LIMITED FORBEARANCE AGREEMENT is made as of November 21, 2018 (this “Agreement”), among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors (as defined in the Loan Agreement referred to below) party hereto, the Lenders (as defined in the Loan Agreement referred to below), and CRG Servicing LL |
|
| November 26, 2018 |
8-K 1 a18-4062018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdicti |
|
| November 19, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a18-4042718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdicti |
|
| November 19, 2018 |
Exhibit 10.1 [EXECUTION VERSION ] AMENDMENT AND WAIVER NO. 6 THIS AMENDMENT AND WAIVER, dated as of November 16, 2018 (this “Agreement”), is made among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors as from time to time party hereto, the Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Le |
|
| November 14, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a18-4020718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdicti |
|
| November 14, 2018 |
Exhibit 10.1 [EXECUTION VERSION ] AMENDMENT AND WAIVER NO. 5 THIS AMENDMENT AND WAIVER, dated as of November 13, 2018 (this “Agreement”), is made among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors as from time to time party hereto, the Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Le |
|
| November 9, 2018 |
Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results and Business Update Exhibit 99.1 Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results and Business Update NEW YORK, November 8, 2018 —Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended September 30, 2018. Thi |
|
| November 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-3989918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| November 9, 2018 |
SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) is by and between Marino Garcia (“Employee”) and Synergy Pharmaceuticals, Inc. |
|
| November 9, 2018 |
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT CERTAIN PORTIONS OF THIS EXHIBIT, INDICATED BY THE MARK [*], HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION WILL BE FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. |
|
| November 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2018 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35268 SYNERGY |
|
| November 9, 2018 |
SEPARATION AGREEMENT This Separation Agreement (the “Agreement”), dated October 30, 2018, is by and between Gary Jacob (“Executive”) and Synergy Pharmaceuticals Inc. |
|
| November 6, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 Synergy Pharmaceuticals Inc. |
|
| November 6, 2018 |
Exhibit 10.1 WAIVER NO. 4 THIS WAIVER (this “Agreement”), dated as of November 6, 2018 (the “Effective Date”), is made among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors as from time to time party hereto, the Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”), and CRG Servicing |
|
| November 1, 2018 |
Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman Exhibit 99.1 Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman NEW YORK — October 31, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Melvin K. Spigelman, M.D., who has served as an Independent Director of Synergy since August 2008, will now a |
|
| November 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2018 Synergy Pharmaceuticals Inc. |
|
| October 31, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a18-3721528k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| October 31, 2018 |
Exhibit 10.1 AMENDMENT AND WAIVER NO. 3 THIS AMENDMENT AND WAIVER (this “Agreement”), dated as of October 30, 2018 and effective as of October 25, 2018 (the “Effective Date”), is made among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors as from time to time party hereto, the Lenders listed on the signature pages hereof under the heading “LENDERS” (each |
|
| October 25, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2018 Synergy Pharmaceuticals Inc. |
|
| October 25, 2018 |
Synergy Pharmaceuticals Provides Business Update Exhibit 99.1 Synergy Pharmaceuticals Provides Business Update NEW YORK — October 25, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the “Company” or “Synergy”), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today provided a business update. Strategic Review Update In April 2015, prior to the FDA approval and launch of TR |
|
| October 9, 2018 |
Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® (plecanatide) in Two Patient Populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting New analyses results reinforce effectiveness and safety for the use of TRULANCE in adults with CIC or IBS-C NEW YORK — October 8, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP |
|
| October 9, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 a18-3644718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| October 1, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 a18-3610818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| October 1, 2018 |
Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals to Present New Analyses of TRULANCE® (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting New analyses further reinforce effectiveness and safety in important subpopulations of adults with CIC or IBS-C NEW YORK — October 1, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused o |
|
| September 24, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2018 Synergy Pharmaceuticals Inc. |
|
| September 24, 2018 |
Exhibit 99.1 Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access Wins NEW YORK — September 24, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced several new formulary wins improving TRULANCE 2018 and 2019 coverage s |
|
| September 21, 2018 |
8-K 1 a18-3125118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdict |
|
| August 31, 2018 |
EX-10.1 2 a18-240711ex10d1.htm EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 2 THIS AMENDMENT NO. 2 (this “Agreement”), dated as of August 28, 2018, is made among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors as from time to time party hereto, the Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, col |
|
| August 31, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a18-2407118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2018 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdicti |
|
| August 8, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2018 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 7, 2018 |
Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update EX-99.1 2 a18-184071ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update · TRULANCE® second quarter net sales up over 40% versus prior quarter · TRULANCE added to Express Scripts 2019 National Preferred Formulary List · Synergy secures ex-US licensing deal for TRULANCE in China - providing $12 million upfront payment and potentia |
|
| August 7, 2018 |
EX-99.2 3 a18-184071ex99d2.htm EX-99.2 Exhibit 99.2 SYNERGY PHARMACEUTICALS ANNOUNCES LICENSE AGREEMENT WITH LUOXIN PHARMACEUTICAL GROUP FOR TRULANCE® (PLECANATIDE) IN CHINA NEW YORK, NY - August 7, 2018 - Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced today that the company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin) providing Luoxin e |
|
| August 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 a18-1840718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| August 7, 2018 |
EX-99.3 4 a18-184071ex99d3.htm EX-99.3 Exhibit 99.3 SYNERGY PHARMACEUTICALS ANNOUNCES TRULANCE® (PLECANATIDE) ADDED TO EXPRESS SCRIPTS 2019 NATIONAL PREFERRED FORMULARY LIST NEW YORK, NY, August 7, 2018 - Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that leading U.S. pharmacy benefit manager, Express Scripts, will add TRULANCE to its National Preferred Formulary List, effective Janu |
|
| June 13, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a18-1530218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction ( |
|
| June 13, 2018 |
Synergy Pharmaceuticals Announces Amendment to CRG Debt Agreement Exhibit 99.1 Synergy Pharmaceuticals Announces Amendment to CRG Debt Agreement NEW YORK, June 13, 2018 —Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has received a waiver to extend the draw down date of the second borrowing under its Term Loan Agreement wit |
|
| June 13, 2018 |
Form of Waiver No 2 dated as of June 12, 2018. EX-10.1 2 a18-153021ex10d1.htm EX-10.1 Exhibit 10.1 Execution Version WAIVER NO. 2 THIS WAIVER (this “Agreement”), dated as of June 12, 2018, is made among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors as from time to time party hereto, the Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the |
|
| June 12, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 sgyp-8kproxyvote.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdicti |
|
| June 6, 2018 |
Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C) NEW YORK — June 5, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointe |
|
| June 6, 2018 |
Exhibit 99.2 NEWS RELEASE Synergy Pharmaceuticals to Present New Analysis of Therapeutic Risk and Benefit of TRULANCE® (plecanatide) and Linaclotide in Chronic Idiopathic Constipation (CIC) Patients at Digestive Disease Week (DDW) NEW YORK — June 5, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointest |
|
| June 6, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 a18-1447828k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction (C |
|
| May 31, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. DEFA14A DEFA14A 1 proxy-addlmaterialsreminder.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| May 29, 2018 |
Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals to Present New Data at Digestive Disease Week (DDW) Data includes a late-breaking abstract to highlight novel science linking depressed levels of uroguanylin with CIC and IBS-C Additional data reveals long-term results reinforcing the safety and effectiveness data for TRULANCE® (plecanatide) NEW YORK — May 29, 2018 — Synergy Pharmaceuticals Inc. (N |
|
| May 29, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2018 Synergy Pharmaceuticals Inc. |
|
| May 15, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 10, 2018 |
Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update EX-99.1 2 a18-132951ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update · TRULANCE only CIC/IBS-C Rx brand to grow in total and new Rx volume quarter-over-quarter, per IQVIA · Synergy lowers 2018 adjusted operating expense (non-GAAP) guidance · Initiated strategic partnership with the National Cancer Institute (NCI) to collaborat |
|
| May 10, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2018 Synergy Pharmaceuticals Inc. |
|
| May 10, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2018 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| April 20, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 20, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 10, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ý Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 20, 2018 |
OPPENHEIMER 28TH ANNUAL HEALTHCARE CONFERENCE March 20, 2018 Exhibit 99.1 OPPENHEIMER 28TH ANNUAL HEALTHCARE CONFERENCE March 20, 2018 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainti |
|
| March 20, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a18-873418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction ( |
|
| March 13, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 a18-807918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction ( |
|
| March 13, 2018 |
Synergy Pharmaceuticals to Present at Oppenheimer 28th Annual Healthcare Conference EX-99.1 2 a18-80791ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals to Present at Oppenheimer 28th Annual Healthcare Conference NEW YORK, March 13, 2018 —Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Troy Hamilton, Chief Executive Officer of Synergy, will present a corporate update at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m |
|
| March 1, 2018 |
EX-99.1 2 a18-74031ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update – TRULANCE® U.S. net sales were $9.4 million in the fourth quarter, totaling $16.8 million for 2017 – 2017 total prescription volume increased 70% on average month-over-month since launch – Successfully amended CRG debt facility to provide enhan |
|
| March 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-740318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction (C |
|
| March 1, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED: DECEMBER 31, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35268 SYNE |
|
| March 1, 2018 |
Exhibit 21 Synergy Advanced Pharmaceuticals, Inc., a Delaware corporation SMRH:226193008.1 1 |
|
| March 1, 2018 |
SEVENTH AMENDED EXECUTIVE EMPLOYMENT AGREEMENT SEVENTH AMENDED EXECUTIVE EMPLOYMENT AGREEMENT This SEVENTH AMENDED EXECUTIVE EMPLOYMENT AGREEMENT (the “Seventh Amendment”) dated the 18th day of December 2017 (the “Effective Date”) by and between Synergy Pharmaceuticals Inc. |
|
| March 1, 2018 |
EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) dated as of December 22, 2017 is made and entered into by and between Synergy Pharmaceuticals, Inc. |
|
| March 1, 2018 |
[EXECUTION VERSION] AMENDMENT NO. 1 THIS AMENDMENT (this “Agreement”), dated as of February 26, 2018, is made among Synergy Pharmaceuticals Inc., a Delaware corporation (“Borrower”), the Subsidiary Guarantors as from time to time party hereto, the Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”), and CRG Servicing LLC, a De |
|
| February 15, 2018 |
LEERINK HEALTHCARE CONFERENCE February 15, 2018 Exhibit 99.1 LEERINK HEALTHCARE CONFERENCE February 15, 2018 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could |
|
| February 15, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a18-605728k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| February 13, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 a18-605718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| February 13, 2018 |
Synergy Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Exhibit 99.1 Synergy Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK, February 13, 2018 ?Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the Compensation Committee of the Board of Directors of Synergy approved the grant of |
|
| February 13, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment synergypharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Synergy Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 871639308 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check th |
|
| February 9, 2018 |
SGYP / Synergy Pharmaceuticals, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 a18-554911sc13ga.htm SC 13G/A CUSIP No: 871639308 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Titl |
|
| February 1, 2018 |
Exhibit 99.1 Synergy Pharmaceuticals Achieves Cash Balance Requirement to Access Additional Capital Announces Upcoming Investor Events NEW YORK, February 1, 2018 ?Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has met the cash balance requirement to access ad |
|
| February 1, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2018 Synergy Pharmaceuticals Inc. |
|
| January 25, 2018 |
Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals Announces FDA Approval of TRULANCE? (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults NEW YORK ? JANUARY 25, 2018 ? Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE? (plecanatide) 3 mg tablet for the once-daily treatment of |
|
| January 25, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2018 Synergy Pharmaceuticals Inc. |
|
| January 25, 2018 |
EX-99.1 2 a18-38181ex99d1.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals Announces FDA Approval of TRULANCE® (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults NEW YORK — JANUARY 25, 2018 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE® (plecanatide) 3 mg |
|
| January 25, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 a18-381818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| January 22, 2018 |
8-K 1 a18-356318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2018 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| December 19, 2017 |
Exhibit 99.1 Synergy Pharmaceuticals Appoints Troy Hamilton Chief Executive Officer Co-Founder Gary S. Jacob, Ph.D., Named Executive Chairman NEW YORK, December 19, 2017 ? Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Troy Hamilton, Pharm.D., previously Executi |
|
| December 19, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2017 Synergy Pharmaceuticals Inc. |
|
| December 12, 2017 |
SGYP / Synergy Pharmaceuticals, Inc. / PAULSON & CO. INC. - DECEMBER 11, 2017 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 871639308 (CUSIP Number) November 30, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| November 22, 2017 |
SGYP / Synergy Pharmaceuticals, Inc. / CVI Investments, Inc. - SC 13G Passive Investment SC 13G 1 a17-273971sc13g.htm SC 13G CUSIP No: 871639308 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of C |
|
| November 14, 2017 |
EX-1.1 2 a17-270651ex1d1.htm EX-1.1 Exhibit 1.1 EXECUTION COPY 21,705,426 Shares of Common Stock 21,705,426 Warrants to Purchase 21,705,426 Shares of Common Stock SYNERGY PHARMACEUTICALS INC. Common Stock UNDERWRITING AGREEMENT November 13, 2017 JEFFERIES LLC As Representative of the Several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: 1. Introdu |
|
| November 14, 2017 |
Form of Warrant Agency Agreement (including the form of Warrant certificate) EX-4.1 3 a17-270651ex4d1.htm EX-4.1 Exhibit 4.1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT made as of November 15, 2017 (the “Issuance Date”), between Synergy Pharmaceuticals Inc., a Delaware corporation, with offices at 420 Lexington Avenue, Suite 2012, New York, NY 10170 (“Company”), and Philadelphia Stock Transfer, Inc., with offices at 2320 Haverford Rd, Suite 230, Ardmore, PA 19003 (“W |
|
| November 14, 2017 |
Exhibit 99.1 SYNERGY PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS NEW YORK, NY ? November 13, 2017 ? Synergy Pharmaceuticals Inc. (Nasdaq: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, today announced the pricing of its underwritten offering of 21,705,426 shares of its common stock together wit |
|
| November 14, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2017 Synergy Pharmaceuticals Inc. |
|
| November 14, 2017 |
Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS CALCULATION OF REGISTRATION FEE Title of securitiese to be registered(1) Amount to be registered Proposed maximum offering price per share Proposed maximum aggregate offering price Amount of registration fee Common Stock, par value $0. |
|
| November 13, 2017 |
Form of Subordinated Indenture Exhibit 4.2 SYNERGY PHARMACEUTICALS INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Ce |
|
| November 13, 2017 |
Statement Regarding Computation of Ratio of Earnings to Fixed Charges Exhibit 12.1 STATEMENT RE: RATIO OF EARNINGS TO FIXED CHARGES The following table sets forth, for each of the periods presented, our deficiency of earnings to cover fixed charges. Our earnings were insufficient to cover fixed charges for the nine months ended September 30, 2017 and the years ended December 31, 2016, 2015, 2014, 2013 and 2012. Nine Months Ended September 30, Year Ended December 31, |
|
| November 13, 2017 |
EX-4.1 2 a17-263901ex4d1.htm EX-4.1 Exhibit 4.1 SYNERGY PHARMACEUTICALS INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.1 Designation and Terms of Securities 3 Section 2.2 Form of |
|
| November 13, 2017 |
As filed with the Securities and Exchange Commission on November 13, 2017 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2017 Registration No. |
|
| November 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a17-2632118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| November 9, 2017 |
Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update Exhibit 99.1 Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update NEW YORK, November 9, 2017 ?Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended September 30, 2017. ?We |
|
| November 9, 2017 |
sgypex1019301710q |
|
| November 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 9, 2017 |
TABLE OF CONTENTS (continued) Page EXECUTION VERSION TERM LOAN AGREEMENT dated as of September 1, 2017 among SYNERGY PHARMACEUTICALS INC. |
|
| November 1, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 a17-2497118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| November 1, 2017 |
Exhibit 99.1 Synergy Pharmaceuticals to Report Third Quarter 2017 Financial Results and Host Conference Call and Webcast NEW YORK, November 1, 2017 ?Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced it intends to release third quarter 2017 financial results after the NASDAQ market close on Thursday, November 9, 2017. The Company will host a conference call and webcast to discuss its fina |
|
| October 4, 2017 |
SGYP / Synergy Pharmaceuticals, Inc. ESP CORRESP 1 filename1.htm Sheppard Mullin Richter & Hampton LLP 30 Rockefeller Plaza New York, NY 10112-0015 October 4, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Sharon Blume Re: Synergy Pharmaceuticals Inc. Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 1, 2017 Form 10-Q for the Quarterly Period Ended June 30, 2017 Filed August |
|
| September 6, 2017 |
Synergy Pharmaceuticals to Present at Upcoming September Investment Conferences EX-99.1 2 a17-213751ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals to Present at Upcoming September Investment Conferences NEW YORK, September 6, 2017 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present corporate updates at three upcoming investment conferences in New York City during September: Rodman & Renshaw 19th Annual Global Investment Confere |
|
| September 6, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2017 Synergy Pharmaceuticals Inc. |
|
| September 5, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2017 Synergy Pharmaceuticals Inc. |
|
| September 5, 2017 |
Synergy Pharmaceuticals Secures $300 Million Debt Financing Exhibit 99.1 Synergy Pharmaceuticals Secures $300 Million Debt Financing NEW YORK, September 5, 2017 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), announced today that the Company has closed on a $300 million debt financing structured as senior secured loans from CRG LP, a healthcare focused investment firm, and its lender syndicate. This non-dilutive financing enhances our cash position and prov |
|
| August 17, 2017 |
S-8 1 a17-202881s8.htm S-8 As filed with the Securities and Exchange Commission on August 17, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYNERGY PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 33-0505269 (State or other jurisdiction of incorpor |
|
| August 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2017 Synergy Pharmaceuticals Inc. |
|
| August 9, 2017 |
Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update EX-99.1 2 a17-199691ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update · TRULANCE™ (plecanatide) U.S. net sales of $2.3 million in second quarter of 2017 · Total TRULANCE monthly prescription volume has increased on average more than 182% month-over-month since launch in March 2017 · TRULANCE supplemental new drug application ( |
|
| August 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| July 7, 2017 |
8-K 1 a17-1700418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction (C |
|
| July 7, 2017 |
EX-3.1 2 a17-170041ex3d1.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SYNERGY PHARMACEUTICALS INC. (a Delaware Corporation) PURSUANT TO SECTIONS 242 OF THE DELAWARE GENERAL CORPORATION LAW SYNERGY PHARMACEUTICALS INC., a corporation existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that: 1. Th |
|
| June 28, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 a17-1585518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction ( |
|
| June 7, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2017 Synergy Pharmaceuticals Inc. |
|
| June 7, 2017 |
EX-99.1 2 a17-148781ex99d1.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE™ (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C) NEW YORK — June 07, 2017 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) |
|
| June 2, 2017 |
Synergy Pharmaceuticals DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 30, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 a17-1438818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction (C |
|
| May 30, 2017 |
Synergy Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference Exhibit 99.1 Synergy Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference NEW YORK, May 30, 2017 ? Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present a corporate update at the Jefferies Global Healthcare Conference in New York City on Thursday, June 8, 2017 at 2:00 p.m. Eastern Time. A live webcast of the presentation will be accessib |
|
| May 26, 2017 |
SEPARATION AND RELEASE AGREEMENT Exhibit 10.1 Execution Version SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (the ?Agreement?) is by and between Kunwar Shailubhai (?Executive?) and Synergy Pharmaceuticals Inc., a Delaware corporation (the ?Company?). WHEREAS, Executive?s status as an employee of the Company will end effective on May 23, 2017 (the ?Termination Date?); and WHEREAS, Executive and the Compan |
|
| May 26, 2017 |
8-K 1 a17-1414418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction (C |
|
| May 11, 2017 |
Synergy Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 Synergy Pharmaceuticals Inc. |
|
| May 11, 2017 |
Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update Exhibit 99.1 Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update NEW YORK, May 10, 2017 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2017. The first |
|
| May 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 9, 2017 |
Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals to Present Positive TRULANCE? (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) New data highlight efficacy and safety results from Phase 3 trials. NEW YORK ? May 9, 2017 ? Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company will present late-br |
|
| May 9, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 Synergy Pharmaceuticals Inc. |
|
| May 8, 2017 |
EX-99.1 2 a17-123712ex99d1.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Synergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician Perceptions and Experiences with Chronic Idiopathic Constipation (CIC) Results from the BURDEN-CIC Study highlight the condition’s impact and show need for additional CIC treatment options. NEW YORK — May 7, 2017 — Synergy Pharmaceuticals In |
|
| May 8, 2017 |
Exhibit 99.2 NEWS RELEASE Synergy Pharmaceuticals to Present TRULANCE? (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC) with Moderate to Very Severe Bloating New data highlight results for CIC patients with moderate to very severe bloating. NEW YORK ? May 7, 2017 ? Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced |
|
| May 8, 2017 |
Synergy Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2017 Synergy Pharmaceuticals Inc. |
|
| May 3, 2017 |
Synergy Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2017 Synergy Pharmaceuticals Inc. |
|
| May 3, 2017 |
DEUTSCHE BANK HEALTHCARE CONFERENCE Gary Jacob Chairman & CEO May 3, 2017 Exhibit 99.1 DEUTSCHE BANK HEALTHCARE CONFERENCE Gary Jacob Chairman & CEO May 3, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks an |
|
| April 28, 2017 |
Synergy Pharmaceuticals DEFA14A DEFA14A 1 a17-21142defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as |
|
| April 28, 2017 |
Synergy Pharmaceuticals DEF 14A DEF 14A 1 a17-21141def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as |
|
| April 24, 2017 |
Synergy Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2017 Synergy Pharmaceuticals Inc. |
|
| April 24, 2017 |
Synergy Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Healthcare Conference Exhibit 99.1 Synergy Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Healthcare Conference NEW YORK, April 24, 2017 ? Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present a corporate update at the 42nd Annual Deutsche Bank Healthcare Conference in Boston on Wednesday, May 3, 2017 at 12:50 p.m. Eastern Time. A live webcast of the presentation will be |
|
| April 17, 2017 |
Synergy Pharmaceuticals PRE 14A PRE 14A 1 a17-21141pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as |
|
| April 17, 2017 |
Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer EX-99.1 3 a17-114161ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer NEW YORK, April 17, 2017 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary G. Gemignani has been appointed as Executive Vice President and Chief Financial Officer, effective April 17, 2017. Mr. Gemignani replaces Senior Vice President, Finance, Bern |
|
| April 17, 2017 |
8-K 1 a17-1141618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| April 17, 2017 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) dated as of April 17 , 2017 is made and entered into by and between Synergy Pharmaceuticals, Inc., a company incorporated under the laws of the state of Delaware (the ?Company?), and Gary G. Gemignani, an individual (the ?Executive?). WITNESSETH: The Company desires to employ the Executive, and the Ex |
|
| April 12, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 a17-1125318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| April 12, 2017 |
EX-99.1 2 a17-112531ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCETM (Plecanatide) Patent Protection Until 2032 NEW YORK, April 12, 2017 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the United States Patent and Trademark Office (USPTO) has issued three new patents covering TRULANCE (plecanatide). The |
|
| April 6, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 a17-1099118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction ( |
|
| April 6, 2017 |
EX-99.1 2 a17-109911ex99d1.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Synergy Pharmaceuticals Launches the Poop Troop, the First Emoji Keyboard Designed to Support Dialogue Around Chronic Idiopathic Constipation (CIC) NEW YORK — APRIL 6, 2017 — Synergy Pharmaceuticals today announced the launch of the Poop Troop, a series of 14 animated emojis designed to encourage conversation and allow people to bett |
|
| March 27, 2017 |
EX-99.1 2 a17-99291ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for TRULANCE™ (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C) NEW YORK — March 27, 2017 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company has submitted a supplemental New Drug Application (sNDA) for |
|
| March 27, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 a17-992918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction ( |
|
| March 21, 2017 |
OPPENHEIMER HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer March 21, 2017 Exhibit 99.1 OPPENHEIMER HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer March 21, 2017 SAFE HARBOR STATEMENT 2 This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are |
|
| March 21, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2017 Synergy Pharmaceuticals Inc. |
|
| March 14, 2017 |
Synergy Pharmaceuticals to Present at Oppenheimer 27th Annual Healthcare Conference EX-99.1 2 a17-74972ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals to Present at Oppenheimer 27th Annual Healthcare Conference NEW YORK, N.Y., March 14, 2017 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Marino Garcia, the company’s EVP and Chief Strategy Officer, will present a corporate update at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, |
|
| March 14, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2017 Synergy Pharmaceuticals Inc. |
|
| March 2, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2017 Synergy Pharmaceuticals Inc. |
|
| March 2, 2017 |
Synergy Pharmaceuticals Reports Fourth Quarter 2016 Financial Results and Business Update Exhibit 99.1 Synergy Pharmaceuticals Reports Fourth Quarter 2016 Financial Results and Business Update NEW YORK, March 1, 2017 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended December 31, 2016. The a |
|
| March 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED: DECEMBER 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35268 SYNE |
|
| March 1, 2017 |
AMENDED AND RESTATED BYLAWS OF SYNERGY PHARMACEUTICALS INC. A Delaware Corporation ARTICLE I: OFFICES SECTION 1.1 Registered Office. The registered office of Synergy Pharmaceuticals Inc. ("Corporation") shall be at Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle, Delaware 19801. The registered agent of the corporation in the State of Delaware at such address is The C |
|
| March 1, 2017 |
Execution Version SYNERGY PHARMACEUTICALS INC. AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 28, 2017 to Indenture Dated as of November 3, 2014 7.50% Convertible Senior Notes due 2019 THIS FIRST SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), dated as of February 28, 2017, is between Synergy Pharmaceuticals Inc., a Delaware corpora |
|
| March 1, 2017 |
EX-21 6 exhibit21.htm EXHIBIT 21 Exhibit 21 Synergy Advanced Pharmaceuticals, Inc., a Delaware corporation SMRH:226193008.1 1 |
|
| March 1, 2017 |
FIFTH AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT FIFTH AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This FIFTH AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement") dated December 29, 2016 by and between Synergy Pharmaceuticals Inc. |
|
| March 1, 2017 |
SYNERGY PHARMACEUTICALS INC. CODE OF BUSINESS CONDUCT AND ETHICS EX-14 5 synergycodeofbusinesscondu.htm EXHIBIT 14 SYNERGY PHARMACEUTICALS INC. CODE OF BUSINESS CONDUCT AND ETHICS 1. Introduction We are committed to maintaining the highest standards of ethical, honest and legal business conduct. This Code of Business Conduct and Ethics (“Code”) reflects the business practices and principles of behavior that support this commitment. We expect all employees, incl |
|
| February 15, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a17-454318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| February 15, 2017 |
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 EX-99.1 2 a17-45431ex99d1.htm EX-99.1 Exhibit 99.1 LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securit |
|
| February 14, 2017 |
Synergy Pharmaceuticals 3G/A (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 871639308 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 14, 2017 |
SGYP / Synergy Pharmaceuticals, Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 871639308 (CUSIP Number) December 31, 2016 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 14, 2017 |
SGYP / Synergy Pharmaceuticals, Inc. / PAULSON & CO. INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 871639308 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 13, 2017 |
SC 13G/A 1 p17-0605sc13ga.htm SYNERGY PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* SYNERGY PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 871639308 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of This Statement) Check the approp |
|
| February 13, 2017 |
Synergy Pharmaceuticals 13G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 sgyp123116a2.htm 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 871639308 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 10, 2017 |
SGYP / Synergy Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 synergypharmaceuticalsinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Synergy Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 871639308 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropriate box to designate th |
|
| February 8, 2017 |
Synergy Pharmaceuticals to Present at Leerink Partners 6th Annual Global Healthcare Conference Exhibit 99.1 Synergy Pharmaceuticals to Present at Leerink Partners 6th Annual Global Healthcare Conference NEW YORK FEBRUARY 8, 2017 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Marino Garcia, the companys EVP and Chief Strategy Officer, will participate in a fireside chat at Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 11:00 |
|
| February 8, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2017 Synergy Pharmaceuticals Inc. |
|
| February 7, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 a17-395018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| February 7, 2017 |
Exhibit 99.1 Pivotal Phase 3 Data Results for TRULANCE (plecanatide) in the Treatment of Chronic Idiopathic Constipation (CIC) Published in American Journal of Gastroenterology NEW YORK FEBRUARY 7, 2017 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that demonstrated the effic |
|
| February 2, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 a17-252738k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| February 2, 2017 |
Exhibit 99.1 SYNERGY PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK NEW YORK, NY January 31, 2017 - Synergy Pharmaceuticals Inc. (Nasdaq: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced an agreement to sell $125 million of its common stock to an underwriting syndicate led by Cantor F |
|
| February 2, 2017 |
20,325,204 Shares SYNERGY PHARMACEUTICALS INC. Common Stock UNDERWRITING AGREEMENT Exhibit 1.1 20,325,204 Shares SYNERGY PHARMACEUTICALS INC. Common Stock UNDERWRITING AGREEMENT January 31, 2017 CANTOR FITZGERALD & CO. As Representative of the Several Underwriters c/o CANTOR FITZGERALD & CO. 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: 1. Introductory. Synergy Pharmaceuticals Inc., a Delaware corporation (Company), agrees with Cantor Fitzgerald & Co., as the |
|
| February 2, 2017 |
EX-99.2 5 a17-25273ex99d2.htm EX-99.2 Exhibit 99.2 SYNERGY PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK NEW YORK, NY — February 1, 2017 — Synergy Pharmaceuticals Inc. (Nasdaq: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the pricing of its underwritten public offering of 20,325, |
|
| February 2, 2017 |
20,325,204 Shares Common Stock 424B5 1 a2230823z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-205484 Prospectus Supplement (To Prospectus Dated July 14, 2015) 20,325,204 Shares Common Stock We are offering 20,325,204 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market |
|
| January 31, 2017 |
SUBJECT TO COMPLETION, DATED JANUARY 31, 2017 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 20, 2017 |
EX-99.1 2 a17-27701ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals’ TRULANCE™ (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK — JANUARY 19, 2017 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE™ (plecanatide) for the treatment of adults with |
|
| January 20, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a17-277018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2017 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| December 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2016 Synergy Pharmaceuticals Inc. |
|
| December 22, 2016 |
Exhibit 99.1 Synergy Pharmaceuticals Announces Positive Results in Second Phase 3 Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) NEW YORK December 22, 2016 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, an inve |
|
| December 22, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 a16-2293528k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2016 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdicti |
|
| December 9, 2016 |
EX-99.1 2 a16-229351ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Announces Positive Results in First Phase 3 Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) NEW YORK — December 9, 2016 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficac |
|
| December 9, 2016 |
8-K 1 a16-2293518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2016 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdictio |
|
| November 21, 2016 |
Exhibit 99.1 EXCHANGE AGREEMENT (the Undersigned), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (Accounts) for whom the Undersigned holds contractual and investment authority (each Account, as well as the Undersigned if it is exchanging Existing Securities (as defined below) hereunder, a Holder), enters into this Exchange Agreement (the Agreement) with Syner |
|
| November 21, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2016 Synergy Pharmaceuticals Inc. |
|
| November 15, 2016 |
EX-99.1 2 a16-216761ex99d1.htm EX-99.1 Exhibit 99.1 EXCHANGE AGREEMENT OrbiMed Advisors LLC and its affiliate OrbiMed Capital LLC (the “Undersigned”), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (“Accounts”) for whom the Undersigned holds contractual and investment authority (each Account, as well as the Undersigned if it is exchanging Existing Securities (as defin |
|
| November 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2016 Synergy Pharmaceuticals Inc. |
|
| November 10, 2016 |
Synergy Pharmaceuticals to Present at Jefferies 2016 London Healthcare Conference Exhibit 99.1 Synergy Pharmaceuticals to Present at Jefferies 2016 London Healthcare Conference NEW YORK, N.Y., November 10, 2016 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced the company will present a corporate update at the Jefferies London Healthcare Conference on Wednesday, November 16, 2016 at 8:00 a.m. GMT. A live webcast of the presentation will be accessible through the Inv |
|
| November 10, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2016 Synergy Pharmaceuticals Inc. |
|
| November 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2016 Synergy Pharmaceuticals Inc. |
|
| November 9, 2016 |
Synergy Pharmaceuticals Reports Third Quarter 2016 Financial Results and Business Update Exhibit 99.1 Synergy Pharmaceuticals Reports Third Quarter 2016 Financial Results and Business Update NEW YORK, November 9, 2016 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended September 30, 2016. Th |
|
| November 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| October 19, 2016 |
CORRESP 1 filename1.htm Synergy Pharmaceuticals, Inc. 420 Lexington Avenue, Suite 2012 New York, NY 10170 October 19, 2016 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Re: Synergy Pharmaceuticals Inc. Registration Statement on Form S-3 File No. 333-214013 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules |
|
| October 17, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2016 Synergy Pharmaceuticals Inc. |
|
| October 17, 2016 |
Exhibit 99.1 Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology (ACG) Annual Scientific Meeting NEW YORK ? OCTOBER 17, 2016 ? Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today presented new long-term safety data of plecanatide, its investigational, orally-administered compound currently being evaluated by th |
|
| October 6, 2016 |
Table of Contents As filed with the Securities and Exchange Commission on October 6, 2016 Registration No. |
|
| October 6, 2016 |
EX-4.1 2 a16-195221ex4d1.htm EX-4.1 Exhibit 4.1 Synergy Pharmaceuticals INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Inc. CUSIP 871639 30 8 SEE REVERSE FOR CERTAIN DEFINITIONS I I • 1 I J I r "-<' I " "tl :;J=: FULLY-PAID AND NONASSESSABLE SHARES OF THE COMMON STOCK, $0.0001 PAR VALUE, OF Jc> m,.... h b b "tl :J: )> en ..... ;>; ..... :IJ 0 ("") Jz> e..n., m :IJ z President ''" ·'" "" I ?§ |
|
| October 5, 2016 |
Synergy Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) EX-99.1 2 a16-195501ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, N.Y., October 5, 2016 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the independent Compensation Committee of the Board of Directors of Synergy approved the grant of an inducement stock option to purchase 50,000 shares of Synergy c |
|
| October 5, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2016 Synergy Pharmaceuticals Inc. |
|
| September 28, 2016 |
Synergy Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2016 Synergy Pharmaceuticals Inc. |
|
| September 28, 2016 |
EX-99.1 2 a16-191541ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program NEW YORK — SEPTEMBER 28, 2016 — Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present new data on plecanatide, an investigational compound for the treatment of chronic idiopath |
|
| September 7, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2016 Synergy Pharmaceuticals Inc. |
|
| September 7, 2016 |
Synergy Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference Exhibit 99.1 Synergy Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference NEW YORK, N.Y., September 7, 2016 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced Marino Garcia, the companys EVP and Chief Strategy Officer, will present a corporate update at the Rodman & Renshaw Conference on Monday, September 12, 2016 at 5:30 p.m. Eastern Time at the Lott |
|
| August 8, 2016 |
Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results and Business Update Exhibit 99.1 Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results and Business Update NEW YORK, August 8, 2016 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended June 30, 2016. Our exci |
|
| August 8, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a16-1639218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2016 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction |
|
| August 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| July 15, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2016 Synergy Pharmaceuticals Inc. |
|
| July 15, 2016 |
Exhibit 99.1 SYNERGY PHARMACEUTICALS PROVIDES UPDATE ON ONGOING FDA REVIEW OF PLECANATIDE CIC NDA AND IBS-C CLINICAL DEVELOPMENT PROGRAM NEW YORK, July 15, 2016 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic idiopathic constipation (CIC). Additio |
|
| June 7, 2016 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2016 Synergy Pharmaceuticals Inc. |
|
| May 27, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2016 Synergy Pharmaceuticals Inc. |
|
| May 27, 2016 |
Exhibit 99.1 Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin NEW YORK(BUSINESS WIRE) Synergy Pharmaceuticals Inc. (SGYP) today presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipat |
|
| May 23, 2016 |
EX-99.2 3 a16-114292ex99d2.htm EX-99.2 Exhibit 99.2 SYNERGY PHARMACEUTICALS PRESENTS NEW PLECANATIDE PHASE 3 DATA IN CHRONIC IDIOPATHIC CONSTIPATION PRESENTED AT DIGESTIVE DISEASE WEEK SAN DIEGO, May 22, 2016 — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced additional results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, the |
|
| May 23, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 a16-1142928k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2016 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction (C |
|
| May 23, 2016 |
Exhibit 99.1 Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week NEW YORK, May 21, 2016 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced additional data from two pivotal phase 3 clinical trials (Study-00 and Study-03) evaluating the efficacy and safety of plecanatide, a once-daily oral tablet, in treating pa |
|
| May 16, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 a16-1142918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction (C |
|
| May 16, 2016 |
SYNERGY PHARMACEUTICALS TO PRESENT NEW PLECANATIDE DATA AT DIGESTIVE DISEASE WEEK 2016 Exhibit 99.1 SYNERGY PHARMACEUTICALS TO PRESENT NEW PLECANATIDE DATA AT DIGESTIVE DISEASE WEEK 2016 NEW YORK, May 16, 2016 ? Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), at D |
|
| May 10, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a16-1094328k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2016 Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-35268 33-0505269 (State or other jurisdiction (C |
|
| May 10, 2016 |
Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update Exhibit 99.1 Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update NEW YORK, May 10, 2016 ?Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2016. ?2016 is of |
|
| May 10, 2016 |
Exhibit 99.1 Synergy Pharmaceuticals Inc. Announces Closing of $89.8 Million Registered Direct Offering of Common Stock NEW YORK, NY May 9, 2016 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has closed a registered direct offering of $89.8 million of com |
|
| May 10, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2016 Synergy Pharmaceuticals Inc. |
|
| May 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 5, 2016 |
29,948,334 Shares Synergy Pharmaceuticals Inc. Common Stock Table of Contents PROSPECTUS SUPPLEMENT (to Prospectus Dated July 14, 2015) Filed Pursuant to Rule 424B5 File No. |
|
| May 5, 2016 |
EX-10.1 3 a16-106701ex10d1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 4, 2016, between Synergy Pharmaceuticals Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WH |
|
| May 5, 2016 |
Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering of Common Stock Exhibit 99.1 Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering of Common Stock NEW YORK, NY May 5, 2016 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has entered into definitive agreements with certain institutional investor |
|
| May 5, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 Synergy Pharmaceuticals Inc. |
|
| April 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2016 Synergy Pharmaceuticals Inc. |
|
| April 27, 2016 |
Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer Exhibit 99.1 Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer NEW YORK, N.Y., April 27, 2016 Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Gary L. Sender has resigned as the companys Chief Financial Officer for personal reasons, effective April 30, 2016. Bernard F. Denoyer, who has served as Senior Vice President of Finance and Secretary at Synergy sin |
